AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes for a potential blockbuster that could be part of a powerful combination ...

AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...

The Eli Lilly drug caused a major drop in the blood levels of Lp(a), but further research is needed to show that it will ...

The company expects next quarter to read out initial data from its Heart-2 trial, which is testing a one-time treatment for ...

Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio ...

Prior to his position at Jazz, Mr. Gaslightwala has held several leadership roles at Amgen Inc., Pfizer Inc., and Johnson & Johnson across multiple brands including Kyprolis ®, Vectibix ®, Neulasta ®, ...

The massive pharmacy benefit manager plans to stop requiring coverage reauthorizations for roughly 80 drugs used to treat ...

AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.

Amgen’s key medicines, like Evenity and Repatha, newer medicines like Tavneos and Tezspire and rare disease drugs, mostly products added from the Horizon acquisition, are driving sales.

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other best ...